FY2028 EPS Estimate for COMPASS Pathways Lowered by Analyst

COMPASS Pathways plc (NASDAQ:CMPS) – Equities researchers at HC Wainwright dropped their FY2028 EPS estimates for shares of COMPASS Pathways in a note issued to investors on Thursday, February 13th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of $0.14 for the year, down from their prior forecast of $0.24. HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for COMPASS Pathways’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for COMPASS Pathways’ FY2029 earnings at $1.63 EPS.

A number of other equities research analysts have also recently commented on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $18.00 price objective on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Maxim Group decreased their target price on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $30.60.

COMPASS Pathways Price Performance

Shares of NASDAQ CMPS opened at $4.57 on Friday. The stock has a market capitalization of $312.68 million, a price-to-earnings ratio of -2.08 and a beta of 2.28. COMPASS Pathways has a 12 month low of $3.16 and a 12 month high of $12.75. The firm’s 50 day simple moving average is $4.10 and its 200-day simple moving average is $5.49. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Virtus ETF Advisers LLC lifted its holdings in COMPASS Pathways by 21.4% in the 4th quarter. Virtus ETF Advisers LLC now owns 16,121 shares of the company’s stock valued at $61,000 after purchasing an additional 2,840 shares in the last quarter. Conservest Capital Advisors Inc. lifted its holdings in COMPASS Pathways by 28.9% in the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock valued at $51,000 after purchasing an additional 3,000 shares in the last quarter. Kennedy Capital Management LLC lifted its holdings in COMPASS Pathways by 22.8% in the 4th quarter. Kennedy Capital Management LLC now owns 33,976 shares of the company’s stock valued at $128,000 after purchasing an additional 6,297 shares in the last quarter. Barclays PLC lifted its holdings in COMPASS Pathways by 2.1% in the 4th quarter. Barclays PLC now owns 419,194 shares of the company’s stock valued at $1,585,000 after purchasing an additional 8,718 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new position in COMPASS Pathways in the 4th quarter valued at $41,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.